Pharmacy Management and Health Care Systems
Domain 6 - Pharmacy Management and Health Care Systems
This domain tests how the system your patient lives in actually works: who pays, who decides what is covered, and how a pharmacy runs safely and sustainably.
The Canadian structure
- The Canada Health Act covers medically necessary hospital and physician services. Drugs dispensed in the community are not insured services under that Act - they are covered by a patchwork of provincial and territorial plans, private employer plans, and out-of-pocket payment.
- Provinces run their own plans with their own formularies and rules (for example the Ontario Drug Benefit, BC PharmaCare, and RAMQ in Quebec), often with deductibles, copayments, and special authorization for expensive drugs.
- National bodies shape access: CADTH, now operating as Canada's Drug Agency, and Quebec's INESSS issue reimbursement recommendations; the pan-Canadian Pharmaceutical Alliance negotiates prices; the Patented Medicine Prices Review Board sets price ceilings. The provincial formulary decides what you can actually dispense.
- Federal programs cover First Nations and Inuit health benefits, veterans, federal inmates, and the military.
Managing the pharmacy
- Formulary decisions weigh comparative efficacy, safety, cost and budget impact. Restricted or prior-authorization status is a coverage question, not a clinical one - separate the two when answering.
- Pharmacoeconomics: cost-minimization (identical outcomes), cost-effectiveness (ICER = extra cost ÷ extra effect), cost-utility (QALYs), and budget impact (total spend across the population).
- Operations: inventory turns and expiry rotation, controlled-drug counts, staffing and skill mix with regulated pharmacy technicians, error reporting with continuous quality improvement, and business continuity planning.
Worked example
Two agents for the same indication: Drug A costs $1,200 per patient-year and yields 0.85 QALYs; Drug B costs $28,000 and yields 0.90 QALYs.
- Calculation: ICER = ($28,000 − $1,200) ÷ (0.90 − 0.85) = $26,800 ÷ 0.05 = $536,000 per QALY.
- Reasoning: that is far above commonly used thresholds (often around $50,000 per QALY), so B is unlikely to be funded without restriction even though it is marginally more effective. Frame the answer as "cost-effective at what price?" rather than "too expensive."
Traps that cost marks
- Assuming "covered by the province" means covered for every patient at every dose.
- Confusing federal price review with provincial formulary listing.
- Ignoring budget impact because the per-patient cost looks small.
- Mixing clinical appropriateness with reimbursement status in a single recommendation.